\documentclass[10pt,a4paper]{article}

% Packages
\usepackage{fancyhdr}           % For header and footer
\usepackage{multicol}           % Allows multicols in tables
\usepackage{tabularx}           % Intelligent column widths
\usepackage{tabulary}           % Used in header and footer
\usepackage{hhline}             % Border under tables
\usepackage{graphicx}           % For images
\usepackage{xcolor}             % For hex colours
%\usepackage[utf8x]{inputenc}    % For unicode character support
\usepackage[T1]{fontenc}        % Without this we get weird character replacements
\usepackage{colortbl}           % For coloured tables
\usepackage{setspace}           % For line height
\usepackage{lastpage}           % Needed for total page number
\usepackage{seqsplit}           % Splits long words.
%\usepackage{opensans}          % Can't make this work so far. Shame. Would be lovely.
\usepackage[normalem]{ulem}     % For underlining links
% Most of the following are not required for the majority
% of cheat sheets but are needed for some symbol support.
\usepackage{amsmath}            % Symbols
\usepackage{MnSymbol}           % Symbols
\usepackage{wasysym}            % Symbols
%\usepackage[english,german,french,spanish,italian]{babel}              % Languages

% Document Info
\author{Hardi (Hardi01)}
\pdfinfo{
  /Title (disease-categorized-drugs.pdf)
  /Creator (Cheatography)
  /Author (Hardi (Hardi01))
  /Subject (Disease Categorized Drugs Cheat Sheet)
}

% Lengths and widths
\addtolength{\textwidth}{6cm}
\addtolength{\textheight}{-1cm}
\addtolength{\hoffset}{-3cm}
\addtolength{\voffset}{-2cm}
\setlength{\tabcolsep}{0.2cm} % Space between columns
\setlength{\headsep}{-12pt} % Reduce space between header and content
\setlength{\headheight}{85pt} % If less, LaTeX automatically increases it
\renewcommand{\footrulewidth}{0pt} % Remove footer line
\renewcommand{\headrulewidth}{0pt} % Remove header line
\renewcommand{\seqinsert}{\ifmmode\allowbreak\else\-\fi} % Hyphens in seqsplit
% This two commands together give roughly
% the right line height in the tables
\renewcommand{\arraystretch}{1.3}
\onehalfspacing

% Commands
\newcommand{\SetRowColor}[1]{\noalign{\gdef\RowColorName{#1}}\rowcolor{\RowColorName}} % Shortcut for row colour
\newcommand{\mymulticolumn}[3]{\multicolumn{#1}{>{\columncolor{\RowColorName}}#2}{#3}} % For coloured multi-cols
\newcolumntype{x}[1]{>{\raggedright}p{#1}} % New column types for ragged-right paragraph columns
\newcommand{\tn}{\tabularnewline} % Required as custom column type in use

% Font and Colours
\definecolor{HeadBackground}{HTML}{333333}
\definecolor{FootBackground}{HTML}{666666}
\definecolor{TextColor}{HTML}{333333}
\definecolor{DarkBackground}{HTML}{E39494}
\definecolor{LightBackground}{HTML}{FBF1F1}
\renewcommand{\familydefault}{\sfdefault}
\color{TextColor}

% Header and Footer
\pagestyle{fancy}
\fancyhead{} % Set header to blank
\fancyfoot{} % Set footer to blank
\fancyhead[L]{
\noindent
\begin{multicols}{3}
\begin{tabulary}{5.8cm}{C}
    \SetRowColor{DarkBackground}
    \vspace{-7pt}
    {\parbox{\dimexpr\textwidth-2\fboxsep\relax}{\noindent
        \hspace*{-6pt}\includegraphics[width=5.8cm]{/web/www.cheatography.com/public/images/cheatography_logo.pdf}}
    }
\end{tabulary}
\columnbreak
\begin{tabulary}{11cm}{L}
    \vspace{-2pt}\large{\bf{\textcolor{DarkBackground}{\textrm{Disease Categorized Drugs Cheat Sheet}}}} \\
    \normalsize{by \textcolor{DarkBackground}{Hardi (Hardi01)} via \textcolor{DarkBackground}{\uline{cheatography.com/212750/cs/46606/}}}
\end{tabulary}
\end{multicols}}

\fancyfoot[L]{ \footnotesize
\noindent
\begin{multicols}{3}
\begin{tabulary}{5.8cm}{LL}
  \SetRowColor{FootBackground}
  \mymulticolumn{2}{p{5.377cm}}{\bf\textcolor{white}{Cheatographer}}  \\
  \vspace{-2pt}Hardi (Hardi01) \\
  \uline{cheatography.com/hardi01} \\
  \end{tabulary}
\vfill
\columnbreak
\begin{tabulary}{5.8cm}{L}
  \SetRowColor{FootBackground}
  \mymulticolumn{1}{p{5.377cm}}{\bf\textcolor{white}{Cheat Sheet}}  \\
   \vspace{-2pt}Not Yet Published.\\
   Updated 30th July, 2025.\\
   Page {\thepage} of \pageref{LastPage}.
\end{tabulary}
\vfill
\columnbreak
\begin{tabulary}{5.8cm}{L}
  \SetRowColor{FootBackground}
  \mymulticolumn{1}{p{5.377cm}}{\bf\textcolor{white}{Sponsor}}  \\
  \SetRowColor{white}
  \vspace{-5pt}
  %\includegraphics[width=48px,height=48px]{dave.jpeg}
  Measure your website readability!\\
  www.readability-score.com
\end{tabulary}
\end{multicols}}




\begin{document}
\raggedright
\raggedcolumns

% Set font size to small. Switch to any value
% from this page to resize cheat sheet text:
% www.emerson.emory.edu/services/latex/latex_169.html
\footnotesize % Small font.


\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Hypertension}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
\seqsplit{Angiotensin-Converting} Enzyme (ACE) Inhibitors & Benazepril, Captopril, Cilazapril, Enalapril, Fosinopril, Lisinopril, Perindopril, Quinapril, Ramipril, Trandolapril \tn 
% Row Count 7 (+ 6)
% Row 2
\SetRowColor{LightBackground}
Alpha\textasciitilde{}1\textasciitilde{}-Adrenergic Antagonists & Doxazosin, Prazosin, Terazosin \tn 
% Row Count 9 (+ 2)
% Row 3
\SetRowColor{white}
Angiotensin Receptor Blockers (ARBs) & Azilsartan, Candesartan, Eprosartan, Irbesartan, Iosartan, Olmesartan, Telmisartan, Valsartan \tn 
% Row Count 14 (+ 5)
% Row 4
\SetRowColor{LightBackground}
Beta\textasciitilde{}1\textasciitilde{}-Adrenergic Antagonists, nonselective & Nadolol, Propranolol, Timolol \tn 
% Row Count 17 (+ 3)
% Row 5
\SetRowColor{white}
Beta\textasciitilde{}1\textasciitilde{}-Adrenergic Antagonists, beta\textasciitilde{}1\textasciitilde{}-selective & Atenolol, Bisoprolol, Metoprolol, Nebivolol \tn 
% Row Count 20 (+ 3)
% Row 6
\SetRowColor{LightBackground}
Beta\textasciitilde{}1\textasciitilde{}-Adrenergic Antagonists, nonselective with intrinsic sympathomimetic activity (ISA) & Pindolol \tn 
% Row Count 25 (+ 5)
% Row 7
\SetRowColor{white}
Beta\textasciitilde{}1\textasciitilde{}-Adrenergic Antagonists, beta\textasciitilde{}1\textasciitilde{}-selective with ISA & Acebutolol \tn 
% Row Count 28 (+ 3)
% Row 8
\SetRowColor{LightBackground}
Beta\textasciitilde{}1\textasciitilde{}-Adrenergic Antagonists with alpha\textasciitilde{}1\textasciitilde{}-blocking activity & Labetalol \tn 
% Row Count 32 (+ 4)
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Hypertension (cont)}}  \tn
% Row 9
\SetRowColor{LightBackground}
Calcium Channel Blockers, dihydropyridine & Amlodipine, Felodipine, Nifedipine \tn 
% Row Count 3 (+ 3)
% Row 10
\SetRowColor{white}
Calcium Channel Blockers, nondihydropyridine & Diltiazem, Verapamil \tn 
% Row Count 6 (+ 3)
% Row 11
\SetRowColor{LightBackground}
Centrally Acting Antihypertensive Agents & Clonidine, Methyldopa \tn 
% Row Count 8 (+ 2)
% Row 12
\SetRowColor{white}
Direct Renin Inhibitors & Aliskiren \tn 
% Row Count 10 (+ 2)
% Row 13
\SetRowColor{LightBackground}
Diuretics, potassium-sparing & Amiloride, Spironolactone \tn 
% Row Count 12 (+ 2)
% Row 14
\SetRowColor{white}
Diuretics, thiazide & Hydrochlorothiazide, Chlorthalidone, Indapamide, Metolazone \tn 
% Row Count 15 (+ 3)
% Row 15
\SetRowColor{LightBackground}
ACE Inhibitors/Calcium Channel Blockers Combinations & \seqsplit{Perindopril/Amlodipine} \tn 
% Row Count 18 (+ 3)
% Row 16
\SetRowColor{white}
ACE \seqsplit{Inhibitors/Diuretics} Combinations & \seqsplit{Cilazapril/Hydrochlorothiazide}, \seqsplit{Enalapril/Hydrochlorothiazide}, \seqsplit{Lisinopril/Hydrochlorothiazide}, \seqsplit{Perindopril/Indapamide}, \seqsplit{Quinapril/Hydrochlorothiazide}, \seqsplit{Ramipril/Hydrochlorothiazide} \tn 
% Row Count 27 (+ 9)
% Row 17
\SetRowColor{LightBackground}
ARB/Diuretic Combination & \seqsplit{Azilsartan/Chlorthalidone}, Candesartan/-, Eprosartan/-, Irbesartan/-, Iosartan/-, Olmesartan/-, Telmisartan/-, \seqsplit{Valsartan/Hydrochlorothiazide} \tn 
% Row Count 34 (+ 7)
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Hypertension (cont)}}  \tn
% Row 18
\SetRowColor{LightBackground}
Beta\textasciitilde{}1\textasciitilde{}-Adrenergic \seqsplit{Antagonist/Diuretics} Combinations & \seqsplit{Atenolol/Chlorthalidone}, \seqsplit{Pindolol/Hydrochlorothiazide} \tn 
% Row Count 3 (+ 3)
% Row 19
\SetRowColor{white}
Calcium Channel Blocker/ARB Combinations & \seqsplit{Amlodipine/Telmisartan} \tn 
% Row Count 5 (+ 2)
% Row 20
\SetRowColor{LightBackground}
Calcium Channel Blocker/HMG-CoA Reductase Inhibitor Combinations & \seqsplit{Amlodipine/Atorvastatin} \tn 
% Row Count 9 (+ 4)
% Row 21
\SetRowColor{white}
Diuretic Combinations & \seqsplit{Hydrochlorothiazide/Amiloride}, \seqsplit{Hydrochlorothiazide/Triamterene}, \seqsplit{Hydrochlorothiazide/Spironolactone} \tn 
% Row Count 14 (+ 5)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Hypertension (High Blood Pressure): A condition where the force of blood against the artery walls is consistently too high.}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Depression}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Antipsychotics, second-generation & Aripiprazole, Brexpiprazole, Olanzapine, Quetiapine (extended), Risperidone \tn 
% Row Count 5 (+ 4)
% Row 2
\SetRowColor{LightBackground}
Dual Action Antidepressants & Bupropion, Mirtazapine \tn 
% Row Count 7 (+ 2)
% Row 3
\SetRowColor{white}
Irreversible Monoamine Oxidase Inhibitors & Phenelzine, Tranylcypromine \tn 
% Row Count 10 (+ 3)
% Row 4
\SetRowColor{LightBackground}
NMDA Receptor Antagonists & Esketamine \tn 
% Row Count 12 (+ 2)
% Row 5
\SetRowColor{white}
Reversible Monoamine Oxidase-A Inhibitor & Moclobemide \tn 
% Row Count 14 (+ 2)
% Row 6
\SetRowColor{LightBackground}
Selective Serotonin Reuptake Inhibitors & Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine (Immediate, Controlled-release), Sertraline \tn 
% Row Count 20 (+ 6)
% Row 7
\SetRowColor{white}
\seqsplit{Serotonin-Norepinephrine} Reuptake Inhibitors & Desvenlafaxine, Duloxetine, Levomilnacipran, Venlafaxine \tn 
% Row Count 23 (+ 3)
% Row 8
\SetRowColor{LightBackground}
Serotonin Modulators & Trazodone, Vilazodone, Vortioxetine \tn 
% Row Count 25 (+ 2)
% Row 9
\SetRowColor{white}
Tricyclic Antidepressants & Amitriptyline, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline, Trimipramine \tn 
% Row Count 30 (+ 5)
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Depression (cont)}}  \tn
% Row 10
\SetRowColor{LightBackground}
Natural Health Products & \seqsplit{S-adenosylmethionine} \tn 
% Row Count 2 (+ 2)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Depression: A mood disorder that causes a persistent feeling of sadness and loss of interest and can interfere with your daily activities}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Attention Deficit Hyperactivity Disorder}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Amphetamine-based Agents & Dextroamphetamine (Immediate, Sustained - release tablets), Lisdexamfetamine, Mixed Salt Amphetamine (Extended Release) \tn 
% Row Count 7 (+ 6)
% Row 2
\SetRowColor{LightBackground}
\seqsplit{Methylphenidate-based} Agents & Methylphenidate (Immediate, Sustained, Controlled, Bilayer Controlled - release tablets) \tn 
% Row Count 12 (+ 5)
% Row 3
\SetRowColor{white}
Alpha\textasciitilde{}2\textasciitilde{}-Adrenergic Agonists & Clonidine, Guanfacine \tn 
% Row Count 14 (+ 2)
% Row 4
\SetRowColor{LightBackground}
Antidepressants, dual action & Bupropion \tn 
% Row Count 16 (+ 2)
% Row 5
\SetRowColor{white}
Antidepressants, \seqsplit{serotonin-norepinephrine} reuptake inhibitors (SNRIs) & Venlafaxine \tn 
% Row Count 20 (+ 4)
% Row 6
\SetRowColor{LightBackground}
Antidepressants, tricyclic & Desipramine, Imipramine, Nortriptyline \tn 
% Row Count 22 (+ 2)
% Row 7
\SetRowColor{white}
Antipsychotics, second-generation & Risperidone \tn 
% Row Count 24 (+ 2)
% Row 8
\SetRowColor{LightBackground}
Norepinephrine Reuptake Inhibitors & Atomoxetine \tn 
% Row Count 26 (+ 2)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Attention-deficit hyperactivity disorder (ADHD): The most common pediatric neuropsychiatric disorder causing inattention, hyperactivity and impulsivity}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{X}
\SetRowColor{DarkBackground}
\mymulticolumn{1}{x{17.67cm}}{\bf\textcolor{white}{Serotonin \& Norepinephrine Reuptake Inhibitor}}  \tn
\SetRowColor{LightBackground}
\mymulticolumn{1}{p{17.67cm}}{\vspace{1px}\centerline{\includegraphics[width=5.1cm]{/web/www.cheatography.com/public/uploads/hardi01_1750190724_Serotonin - NE Reuptake Inhibitor.png}}} \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}-}
\SetRowColor{LightBackground}
\mymulticolumn{1}{x{17.67cm}}{A class of antidepressants that work by blocking the reuptake of the neurotransmitter norepinephrine and dopamine, thus increasing their levels in the brain}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}-}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Rheumatoid Arthritis}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Amino salicylates & Sulfasalazine \tn 
% Row Count 2 (+ 1)
% Row 2
\SetRowColor{LightBackground}
Antimalarial Agents & Hydroxychloroquine \tn 
% Row Count 3 (+ 1)
% Row 3
\SetRowColor{white}
Immunomodulators & Leflunomide, Methotrexate \tn 
% Row Count 5 (+ 2)
% Row 4
\SetRowColor{LightBackground}
B-cell Depletors & Rituximab \tn 
% Row Count 6 (+ 1)
% Row 5
\SetRowColor{white}
Interleukin-1 (IL-1) Inhibitors & Anakinra \tn 
% Row Count 8 (+ 2)
% Row 6
\SetRowColor{LightBackground}
Interleukin-6 (IL-6) Inhibitors & Tocilizumab, Sarilumab \tn 
% Row Count 10 (+ 2)
% Row 7
\SetRowColor{white}
T-cell Costimulation Inhibitors & Abatacept \tn 
% Row Count 12 (+ 2)
% Row 8
\SetRowColor{LightBackground}
Tumor Necrosis Factor-alpha (TNF-alpha) Inhibitors & Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab \tn 
% Row Count 15 (+ 3)
% Row 9
\SetRowColor{white}
Janus Kinase Inhibitors & Baricitinib, Tofacitinib citrate, Upadacitinib \tn 
% Row Count 18 (+ 3)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Rheumatoid Arthritis (RA): A chronic autoimmune disease that primarily affects joints, causing pain, swelling and stiffness}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Osteoarthritis}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Analgesics & Acetaminophen, Morphine, Oxycodone, Tramadol \tn 
% Row Count 4 (+ 3)
% Row 2
\SetRowColor{LightBackground}
COX-2 Inhibitors & Celecoxib \tn 
% Row Count 5 (+ 1)
% Row 3
\SetRowColor{white}
NSAIDs, acetic acid derivatives & Diclofenac, Indomethacin, Sulindac \tn 
% Row Count 7 (+ 2)
% Row 4
\SetRowColor{LightBackground}
NSAIDs, naphthylakanone derivatives & Nubumetone \tn 
% Row Count 9 (+ 2)
% Row 5
\SetRowColor{white}
NSAIDs, oxicams & Piroxicam, Meloxicam \tn 
% Row Count 10 (+ 1)
% Row 6
\SetRowColor{LightBackground}
NSAIDs, propionic acid derivatives & Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen sodium, Tiaprofenic acid \tn 
% Row Count 14 (+ 4)
% Row 7
\SetRowColor{white}
NSAIDs, salicylic acid derivatives & ASA, Diflunisal \tn 
% Row Count 16 (+ 2)
% Row 8
\SetRowColor{LightBackground}
\seqsplit{NSAIDs/Gastroprotection} Combination & \seqsplit{Diclofenac/Misoprostol}, \seqsplit{Naproxen/Esomeprazole} \tn 
% Row Count 19 (+ 3)
% Row 9
\SetRowColor{white}
\seqsplit{Serotonin-Norepinephrine} Reuptake Inhibitors & Duloxetine \tn 
% Row Count 22 (+ 3)
% Row 10
\SetRowColor{LightBackground}
Capsicum Derivatives & Capsaicin \tn 
% Row Count 23 (+ 1)
% Row 11
\SetRowColor{white}
Nonsteroidal Anti-inflammatory Agents & Diclofenac Diethylamine, Diclofenac Sodium \tn 
% Row Count 26 (+ 3)
% Row 12
\SetRowColor{LightBackground}
Corticosteroids, Intra-articular & Betamethasone \seqsplit{acetate/betamethasone} sodium phosphate, Triamcinolone acetonide, Methylprednisolone acetate \tn 
% Row Count 32 (+ 6)
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Osteoarthritis (cont)}}  \tn
% Row 13
\SetRowColor{LightBackground}
\seqsplit{Corticosteroid/Synovial} Fluid Replacement, Intra-articular & Hyaluronic acid/triamcinolone hexacetonide \tn 
% Row Count 3 (+ 3)
% Row 14
\SetRowColor{white}
Synovial Fluid Replacement & Sodium hyaluronate \tn 
% Row Count 5 (+ 2)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Osteoarthritis: Most common type of arthritis, characterized by the gradual breakdown of cartilage in joints (Common affected areas: spine, hands, hips or knees)}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Osteoporosis}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Anabolic Agents & Romosozumab, Teriparatide \tn 
% Row Count 3 (+ 2)
% Row 2
\SetRowColor{LightBackground}
Biphosphonates & Alendronate, Risedronate, Zoledronic Acid \tn 
% Row Count 6 (+ 3)
% Row 3
\SetRowColor{white}
Biphosphonates + Nutritional Supplements & Alendronate/Vitamin D \tn 
% Row Count 8 (+ 2)
% Row 4
\SetRowColor{LightBackground}
Calcitonin Peptides & Calcitonin salmon, subcutaneous \tn 
% Row Count 10 (+ 2)
% Row 5
\SetRowColor{white}
Nutritional Supplements & Calcium, Vitamin D \tn 
% Row Count 12 (+ 2)
% Row 6
\SetRowColor{LightBackground}
RANK Ligand Inhibitors & Denosumab \tn 
% Row Count 14 (+ 2)
% Row 7
\SetRowColor{white}
Selective Estrogen Receptor Modulators & Raloxifene, Conjugated \seqsplit{estrogen/bazedoxifene} \tn 
% Row Count 17 (+ 3)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Osteoporosis: A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture (weakened bone)}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Thyroid Disorders}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Thyroid Hormones & Levothyroxine (L-T\textasciitilde{}4\textasciitilde{}), Liothyronine (T\textasciitilde{}3\textasciitilde{}) \tn 
% Row Count 4 (+ 3)
% Row 2
\SetRowColor{LightBackground}
Antithyroid Agents & Methimazole (MMI), Propylthiouracil (PTU) \tn 
% Row Count 7 (+ 3)
% Row 3
\SetRowColor{white}
Beta\textasciitilde{}1\textasciitilde{}-adrenergic Antagonists, nonselective & Propranolol \tn 
% Row Count 10 (+ 3)
% Row 4
\SetRowColor{LightBackground}
Beta\textasciitilde{}1\textasciitilde{}-adrenergic Antagonists, selective & Atenolol, Metoprolol \tn 
% Row Count 13 (+ 3)
% Row 5
\SetRowColor{white}
Corticosteroids, systemic & Dexamethasone, Hydrocortisone Sodium Succinate \tn 
% Row Count 16 (+ 3)
% Row 6
\SetRowColor{LightBackground}
Iodine & Iodine \tn 
% Row Count 17 (+ 1)
% Row 7
\SetRowColor{white}
Radioactive Iodine & Sodium Iodide \tn 
% Row Count 18 (+ 1)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Thyroid Disorders: Conditions that cause the thyroid to make either too much or too little of the hormones (hyperthyroidism and hypothyroidism). Masses may also appear on the thyroid and can alter the function of the thyroid (thyroid nodules).}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Seizures and Epilepsy}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Barbiturates & Phenobarbital, Primidone \tn 
% Row Count 3 (+ 2)
% Row 2
\SetRowColor{LightBackground}
Benzodiazepines & Clobazam \tn 
% Row Count 4 (+ 1)
% Row 3
\SetRowColor{white}
Carboxylic Acid Derivatives & Valproic Acid, Divalproex Sodium \tn 
% Row Count 6 (+ 2)
% Row 4
\SetRowColor{LightBackground}
Gamma Aminobutyric Acid (GABA) Derivatives & Gabapentin, Vigabatrin \tn 
% Row Count 9 (+ 3)
% Row 5
\SetRowColor{white}
Hydantoin Derivatives & Phenytoin Sodium (immediate \& extended release) \tn 
% Row Count 12 (+ 3)
% Row 6
\SetRowColor{LightBackground}
Iminostilbene Derivatives & Carbamazepine (immediate \& controlled release), Eslicarbazepine acetate, Oxcarbazepine \tn 
% Row Count 17 (+ 5)
% Row 7
\SetRowColor{white}
Succinimide Derivatives & Ethosuximide \tn 
% Row Count 19 (+ 2)
% Row 8
\SetRowColor{LightBackground}
Other Antiseizure Medications & Brivaracetam, Cenobamate, Lacosamide, Lamotrigine, Levetiracetam, Perampanel, Rufinamide, Stiripentol, Topiramate \tn 
% Row Count 25 (+ 6)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Epilepsy: a neurological disorder characterized by predisposition to unprovoked seizures.   \newline - Focal Seizures: Originate in one area of the brain \newline - Generalized Seizures: Originate from both sides of the brain}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Parkinson Disease}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Anticholinergic Agents & Benztropine, Ethopropazine, Trihexyphenidyl \tn 
% Row Count 4 (+ 3)
% Row 2
\SetRowColor{LightBackground}
Catechol-O-Methyl Transferase (COMT) Inhibitors & Entacapone \tn 
% Row Count 7 (+ 3)
% Row 3
\SetRowColor{white}
Dopamine Agonists & Apomorphine Injections, Apomorphine Soluble Film, Bromocriptine, Pramipexole, Ropinirole, Rotigotine \tn 
% Row Count 12 (+ 5)
% Row 4
\SetRowColor{LightBackground}
Levodopa Preparations & Levodopa/Carbidopa (Immediate, Controlled, Intestinal Gel Release), \seqsplit{Levodopa/Benserazide} \tn 
% Row Count 17 (+ 5)
% Row 5
\SetRowColor{white}
Levodopa/COMT Inhibitor Combinations & \seqsplit{Levodopa/Carbidopa/Entacapone} \tn 
% Row Count 19 (+ 2)
% Row 6
\SetRowColor{LightBackground}
Monoamine Oxidase B Inhibitors & Rasagiline, Safinamide, Selegiline (deprenyl) \tn 
% Row Count 22 (+ 3)
% Row 7
\SetRowColor{white}
\seqsplit{N-Methyl-D-Aspartate} (NMDA) Receptor Antagonists & Amantadine \tn 
% Row Count 25 (+ 3)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Parkinson Disease: A chronic neurodegenerative disease with progressive loss of dopaminergic neurons in the substantia nigra (a midbrain structure responsible for movement and reward).}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Heart Failure}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
\seqsplit{Angiotensin-Converting} Enzyme Inhibitors & Enalapril, Lisinopril, Perindopril, Ramipril, Trandolapril \tn 
% Row Count 4 (+ 3)
% Row 2
\SetRowColor{LightBackground}
Angiotensin II Receptor Antagonists & Candesartan, Losartan, Valsartan \tn 
% Row Count 6 (+ 2)
% Row 3
\SetRowColor{white}
Angiotensin Receptor-Neprilysin Inhibitor Combinations & \seqsplit{Valsartan/Sacubitril} \tn 
% Row Count 9 (+ 3)
% Row 4
\SetRowColor{LightBackground}
Beta\textasciitilde{}1\textasciitilde{}-Adrenergic Antagonists & Bisoprolol, Carvedilol, Metoprolol \tn 
% Row Count 11 (+ 2)
% Row 5
\SetRowColor{white}
I\textasciitilde{}f\textasciitilde{} Current Inhibitor & Ivabradine \tn 
% Row Count 13 (+ 2)
% Row 6
\SetRowColor{LightBackground}
Inotropic Agents & Digoxin \tn 
% Row Count 14 (+ 1)
% Row 7
\SetRowColor{white}
Loop Diuretics & Bumetanide, Furosemide, Ethacrynic Acid \tn 
% Row Count 16 (+ 2)
% Row 8
\SetRowColor{LightBackground}
Mineralocorticoid Receptor Antagonists (MRAs) & Eplerenone, Spironolactone \tn 
% Row Count 19 (+ 3)
% Row 9
\SetRowColor{white}
Sodium-Glucose Cotransporters 2 Inhibitors & Dapagliflozin, Empagliflozin \tn 
% Row Count 22 (+ 3)
% Row 10
\SetRowColor{LightBackground}
Soluble Guanylate Cyclase Stimulators & Vericiguat \tn 
% Row Count 24 (+ 2)
% Row 11
\SetRowColor{white}
Thiazides and Related Diuretics & Metolazone \tn 
% Row Count 26 (+ 2)
% Row 12
\SetRowColor{LightBackground}
Vasodilators & Hydralazine, Isosorbide Dinitrate \tn 
% Row Count 28 (+ 2)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Heart Failure: A clinical syndrome characterized by different etiologies and pathophysiology. Common symptoms include dyspnea, fluid retention, fatigue, and some form of structural or functional heart disease.}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Dyslipidemias}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
Angiopoietin-like Protein 3 (ANGPTL3) IInhibitors & Evinacumab \tn 
% Row Count 4 (+ 3)
% Row 2
\SetRowColor{LightBackground}
Cholesterol Absorption Inhibitors & Ezetimibe \tn 
% Row Count 6 (+ 2)
% Row 3
\SetRowColor{white}
Fibrates & Bezafibrate, Fenofibrate, Fenofibrate \seqsplit{(microcoated/micronized/nanocrystals)}, Gemfibrozil \tn 
% Row Count 11 (+ 5)
% Row 4
\SetRowColor{LightBackground}
HMG-CoA Reductase Inhibitors & Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin \tn 
% Row Count 15 (+ 4)
% Row 5
\SetRowColor{white}
Microsomal Triglyceride Transfer Protein Inhibitors & Lomitapide \tn 
% Row Count 18 (+ 3)
% Row 6
\SetRowColor{LightBackground}
Omega-3 Fatty Acid Derivatives & Icosapent Ethyl \tn 
% Row Count 20 (+ 2)
% Row 7
\SetRowColor{white}
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Monoclonal Antibodies & Alirocumab, Evolocumab \tn 
% Row Count 25 (+ 5)
% Row 8
\SetRowColor{LightBackground}
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Small Interfering Ribonucleic Acid (siRNA) & Inclisiran \tn 
% Row Count 31 (+ 6)
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Dyslipidemias (cont)}}  \tn
% Row 9
\SetRowColor{LightBackground}
Resins & Cholestyramine, Colesevelam, Colestipol \tn 
% Row Count 2 (+ 2)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Dyslipidemias: Metabolic abnormalities in the quantity (high or low) or function of lipids or lipoproteins in the blood. The majority of Dyslipidemias results from interaction between environmental and genetic factors.}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Chronic Obstructive Pulmonary Disease (COPD)}}  \tn
% Row 0
\SetRowColor{LightBackground}
{\bf{{\emph{CLASS:}}}} & {\bf{{\emph{DRUG:}}}} \tn 
% Row Count 1 (+ 1)
% Row 1
\SetRowColor{white}
\mymulticolumn{2}{x{17.67cm}}{{\emph{Inhaled Drugs for COPD}}} \tn 
% Row Count 2 (+ 1)
% Row 2
\SetRowColor{LightBackground}
Beta\textasciitilde{}2\textasciitilde{}-Adrenergic Agonists, short-acting (SABA) & Salbutamol, Terbutaline \tn 
% Row Count 5 (+ 3)
% Row 3
\SetRowColor{white}
Muscarinic Antagonists, short-acting (SAMA) & Ipratropium \tn 
% Row Count 8 (+ 3)
% Row 4
\SetRowColor{LightBackground}
Muscarinic Antagonist/Beta\textasciitilde{}2\textasciitilde{}-Adrenergic Agonist Combinations, short acting (SAMA/SABA) & \seqsplit{Ipratropium/Salbutamol} \tn 
% Row Count 13 (+ 5)
% Row 5
\SetRowColor{white}
Beta\textasciitilde{}2\textasciitilde{}-Adrenergic Agonists, Long Acting (LABA) & Formoterol Fumarate Dihydrate, Salmeterol \tn 
% Row Count 16 (+ 3)
% Row 6
\SetRowColor{LightBackground}
Muscarinic Antagonists, Long Acting (LAMA) & Aclidinium, Glycopyrronium, Tiotropium, Umeclidinium \tn 
% Row Count 19 (+ 3)
% Row 7
\SetRowColor{white}
Inhaled Corticosteroids/Beta\textasciitilde{}2\textasciitilde{}-Adrenergic Agonist Combinations, Long Acting (ICS/LABA) & \seqsplit{Budesonide/Formoterol} Fumarate, \seqsplit{Fluticasone/Salmeterol}, \seqsplit{Fluticasone/Vilanterol}, \seqsplit{Mometasone/Indacaterol} \tn 
% Row Count 25 (+ 6)
% Row 8
\SetRowColor{LightBackground}
Muscarinic Antagonist/Beta\textasciitilde{}2\textasciitilde{}-Adrenergic Agonist Combinations, Long-Acting (LAMA/LABA) & \seqsplit{Aclidinium/Formoterol} Fumarate Dihydrate, \seqsplit{Glycopyrronium/Indacaterol}, \seqsplit{Tiotropium/Olodaterol}, \seqsplit{Umeclidinium/Vilanterol} \tn 
% Row Count 31 (+ 6)
\end{tabularx}
\par\addvspace{1.3em}

\begin{tabularx}{17.67cm}{x{8.635 cm} x{8.635 cm} }
\SetRowColor{DarkBackground}
\mymulticolumn{2}{x{17.67cm}}{\bf\textcolor{white}{Chronic Obstructive Pulmonary Disease (COPD) (cont)}}  \tn
% Row 9
\SetRowColor{LightBackground}
Inhaled \seqsplit{Corticosteroids/Muscarinic} Antagonist/Beta\textasciitilde{}2\textasciitilde{}-Adrenergic Agonist Combinations, Long Acting (ICS/LAMA/LABA) & \seqsplit{Budesonide/Glycopyrronium/Formoterol} Fumarate Dihydrate, \seqsplit{Fluticasone/Umeclidinium/Vilanterol}, \seqsplit{Mometasone/Glycopyrronium/Indacaterol} \tn 
% Row Count 7 (+ 7)
% Row 10
\SetRowColor{white}
\mymulticolumn{2}{x{17.67cm}}{{\emph{Oral Drugs for COPD}}} \tn 
% Row Count 8 (+ 1)
% Row 11
\SetRowColor{LightBackground}
Corticosteroids, Systemic & Prednisone \tn 
% Row Count 10 (+ 2)
% Row 12
\SetRowColor{white}
Methylxanthines & Theophylline \tn 
% Row Count 11 (+ 1)
% Row 13
\SetRowColor{LightBackground}
Mucolytics & N-Acetylcysteine \tn 
% Row Count 12 (+ 1)
% Row 14
\SetRowColor{white}
Phosphodiesterase 4 (PDE4) Inhibitors & Roflumilast \tn 
% Row Count 14 (+ 2)
% Row 15
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{{\emph{Oral Antibiotics for Acute Exacerbation of COPD}}} \tn 
% Row Count 15 (+ 1)
% Row 16
\SetRowColor{white}
Penicillin & Amoxicillin, \seqsplit{Amoxicillin/Clavulanate} \tn 
% Row Count 17 (+ 2)
% Row 17
\SetRowColor{LightBackground}
Sulfonamide Combinations & \seqsplit{Sulfamethoxazole/Trimethoprim} \tn 
% Row Count 19 (+ 2)
% Row 18
\SetRowColor{white}
Tetracyclines & Doxycycline \tn 
% Row Count 20 (+ 1)
% Row 19
\SetRowColor{LightBackground}
Cephalosporins & Cefuroxime Axetil \tn 
% Row Count 21 (+ 1)
% Row 20
\SetRowColor{white}
Fluoroquinolones & Ciprofloxacin, Levofloxacin, Moxifloxacin \tn 
% Row Count 24 (+ 3)
% Row 21
\SetRowColor{LightBackground}
Macrolides, Extended Spectrum & Azithromycin, Clarithromycin \tn 
% Row Count 26 (+ 2)
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\SetRowColor{LightBackground}
\mymulticolumn{2}{x{17.67cm}}{Chronic Obstructive Pulmonary Disease (COPD): A systemic disease largely caused by smoking and characterized by progressive, partially reversible airway limitations and increasing frequency and severity of exacerbation.}  \tn 
\hhline{>{\arrayrulecolor{DarkBackground}}--}
\end{tabularx}
\par\addvspace{1.3em}



\end{document}